| Document Type
|
:
|
BL
|
| Record Number
|
:
|
865180
|
| Title & Author
|
:
|
Drug adherence in hypertension and cardiovascular protection /\ Michel Burnier, editor.
|
| Publication Statement
|
:
|
Cham :: Springer,, [2018]
|
|
|
:
|
, ©2018
|
| Series Statement
|
:
|
Updates in hypertension and cardiovascular protection,
|
| Page. NO
|
:
|
1 online resource
|
| ISBN
|
:
|
3319765930
|
|
|
:
|
: 9783319765938
|
|
|
:
|
3319765922
|
|
|
:
|
9783319765921
|
| Contents
|
:
|
Intro; Preface; Contents; 1: Taxonomy of Medication Adherence: Recent Developments; 1.1 Introduction; 1.2 Terminology: The Difficulty of Choosing the Right Term!; 1.3 The New European Consensus-Based terminology; 1.4 Terminologies Associated with the Quantification of Adherence to Medications; References; Part I: Measuring Drug Adherence; 2: Qualitative Assessments of Adherence; 2.1 Introduction; 2.2 What Are the Characteristics of a Valid and Useful Method to Assess Adherence to the Medication?; 2.3 The Patient Interviews by Physicians or Third Parties and Patient's Diaries.
|
|
|
:
|
2.4 Use of Questionnaires in HypertensionReferences; 3: Electronic Monitoring of Medication Adherence: From Dose-Counting to Dose-Clocking; 3.1 History of MEMS Monitoring and Bibliometry; 3.2 Indirect Versus Direct Measure; 3.3 From Reliable Measure to Effective Interventions; 3.4 "Real-Time": What Does It Mean?; References; 4: Measurements of Antihypertensive Medications in Blood and Urine; 4.1 Background; 4.2 Principle of LC-MS/MS; 4.2.1 Sample Derivatisation; 4.2.2 High Performance Liquid Chromatography (HPLC); 4.2.3 Mass Spectrometry (Fig. 4.2).
|
|
|
:
|
4.3 The Biochemical Principles of Assessment of Non-Ưadherence to Antihypertensive Treatment4.4 Laboratory Processing of Samples; 4.5 Detecting Non-adherence to Antihypertensive Treatment; 4.6 Prevalence and Risk Factors of Non-adherence to Antihypertensive Medications: Insights from Biochemical Analysis of Bodily Fluids by HPLC-MS/MS; 4.7 Our Clinical Experience; 4.8 Other Benefits of Biochemical Testing for Non-Ưadherence to Antihypertensive Treatment; 4.9 The Future; References.
|
|
|
:
|
5: Adherence to Antihypertensive and Cardiovascular Preventive Treatment: The Contribution of the Lombardy Database5.1 Adherence to Drug Treatment in Hypertension; 5.2 Adherence and Type of Initial Antihypertensive Monotherapy; 5.3 Factors Involved in Adherence to Antihypertensive Drugs; 5.4 Adherence to Treatment and Cardiovascular Risk; 5.5 Combination Treatment; 5.6 Adherence and Other Cardiovascular Drugs; References; 6: Directly Observed Therapy in Hypertension (DOT-HTN); 6.1 Background and Rationale; 6.1.1 Historical Background of Directly Observed Therapy (DO T).
|
|
|
:
|
6.1.2 DOT in Hypertension6.1.2.1 Safety of DOT in Hypertension; 6.2 Methods; 6.2.1 Research Questions; 6.2.2 Review Methodologies and Literature Search; 6.2.3 Selection Criteria; 6.2.4 Search in International Trials Registries; 6.2.5 Data Extraction from Published Research; 6.3 Results; 6.3.1 Identified Ongoing Trials; 6.3.2 Identified Published Research; 6.3.3 DOT-HTN Procedures Reported in the Reviewed Literature; 6.4 Discussion; References; 7: Digital Medicines to Measure Drug Ingestion Adherence; 7.1 Introduction; 7.2 Digital Medicines; 7.3 Pre-approval Studies.
|
| Abstract
|
:
|
"This book provides a critical and comprehensive review of the methodologies available for measuring drug adherence in clinical practice, including those relying on emerging technologies. The authors discuss the risk factors of non-adherence and shed light on how to identify patients at risk of poor adherence. Drug therapies in chronic diseases rely heavily on the patient's adherence, since drugs that are not taken are ineffective and leave the patient at high risk of developing clinical complications. Given the absence of new drugs for the treatment of hypertension, drug adherence is particularly important in these patients to improve blood pressure control. The book further investigates a new aspect, namely the importance of drug adherence in clinical trials and studies and draws attention to the limits of developing drugs without significant information on drug adherence. Several chapters are dedicated to the importance of adherence in specific forms of hypertension, such as resistant hypertension, dyslipidemia and hypertension associated with cardiovascular risk. As experts confronted with drug adherence in their daily practice, the authors analyse the real effectiveness of several interventions aimed at improving drug adherence and put particular emphasis on the importance of an interdisciplinary approach involving nurses and pharmacists. The volume also includes a careful analysis of the health and economic impact of poor adherence. The book is aimed at physicians, pharmacists, students and all health professionals dealing not only with hypertension or dyslipidemia, but also with chronic asymptomatic diseases such as diabetes, HIV or chronic respiratory diseases."--
|
| Subject
|
:
|
Heart-- Diseases-- Chemotherapy.
|
| Subject
|
:
|
Hypertension-- Chemotherapy.
|
| Subject
|
:
|
Patient compliance.
|
| Subject
|
:
|
Cardiovascular medicine.
|
| Subject
|
:
|
Diabetes.
|
| Subject
|
:
|
Heart-- Diseases-- Chemotherapy.
|
| Subject
|
:
|
Hypertension-- Chemotherapy.
|
| Subject
|
:
|
MEDICAL-- Pharmacology.
|
| Subject
|
:
|
Metabolism.
|
| Subject
|
:
|
Patient compliance.
|
| Subject
|
:
|
Pharmacology.
|
| Subject
|
:
|
Cardiovascular Diseases-- drug therapy.
|
| Subject
|
:
|
Medication Adherence.
|
| Subject
|
:
|
Hypertension-- drug therapy.
|
| Subject
|
:
|
Risk Factors.
|
| Dewey Classification
|
:
|
615.5
|
| LC Classification
|
:
|
R727.43
|
| Added Entry
|
:
|
Burnier, Michel,1953-
|